81 related articles for article (PubMed ID: 26185017)
1. The influence of comorbidity and comedication on grade III/IV toxicity and prior discontinuation of chemotherapy in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Woopen H; Richter R; Chekerov R; Siepmann T; Ismaeel F; Sehouli J
Gynecol Oncol; 2015 Sep; 138(3):735-40. PubMed ID: 26185017
[TBL] [Abstract][Full Text] [Related]
2. Elderly ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Woopen H; Inci G; Richter R; Chekerov R; Ismaeel F; Sehouli J
Eur J Cancer; 2016 Jun; 60():101-6. PubMed ID: 27104667
[TBL] [Abstract][Full Text] [Related]
3. Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients.
Grabowski JP; Richter R; Rittmeister H; Chekerov R; Woopen H; Sehouli J
Anticancer Res; 2018 Oct; 38(10):5853-5858. PubMed ID: 30275210
[TBL] [Abstract][Full Text] [Related]
4. Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213.
Woopen H; Richter R; Chekerov R; Inci G; Alavi S; Grabowski JP; Sehouli J
Support Care Cancer; 2020 Jan; 28(1):73-78. PubMed ID: 30980260
[TBL] [Abstract][Full Text] [Related]
5. The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Woopen H; Richter R; Ismaeel F; Chekerov R; Roots I; Siepmann T; Sehouli J
Gynecol Oncol; 2016 Mar; 140(3):554-8. PubMed ID: 26790772
[TBL] [Abstract][Full Text] [Related]
6. The prognostic and predictive role of pain before systemic chemotherapy in recurrent ovarian cancer: an individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients.
Woopen H; Richter R; Inci G; Alavi S; Chekerov R; Sehouli J
Support Care Cancer; 2020 Apr; 28(4):1997-2003. PubMed ID: 31385100
[TBL] [Abstract][Full Text] [Related]
7. A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Sehouli J; Tomè O; Dimitrova D; Camara O; Runnebaum IB; Tessen HW; Rautenberg B; Chekerov R; Muallem MZ; Lux MP; Trarbach T; Gitsch G
J Cancer Res Clin Oncol; 2017 Mar; 143(3):541-550. PubMed ID: 27896440
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).
Mustea A; Koensgen D; Belau A; Sehouli J; Lichtenegger W; Schneidewind L; Sommer H; Markmann S; Scharf JP; Ehmke M; Ledwon P; Braicu I; Zygmunt M; Koehler G
Cancer Chemother Pharmacol; 2013 Nov; 72(5):975-83. PubMed ID: 23995698
[TBL] [Abstract][Full Text] [Related]
11. Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.
Oskay-Ozcelik G; Chekerov R; Sommer H; Keil E; Einenkel J; Pfisterer J; Lorenz-Schlüter C; Lichtenegger W; Camara O; Sehouli J
Gynecol Oncol; 2010 Mar; 116(3):317-22. PubMed ID: 19959213
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
13. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.
Pietzner K; Richter R; Chekerov R; Erol E; Oskay-Özcelik G; Lichtenegger W; Sehouli J
Anticancer Res; 2011 Aug; 31(8):2679-82. PubMed ID: 21778323
[TBL] [Abstract][Full Text] [Related]
15. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
Sehouli J; Stengel D; Mustea A; Camara O; Keil E; Elling D; Ledwon P; Christiansen B; Klare P; Gebauer G; Schwarz M; Lichtenegger W;
Cancer Chemother Pharmacol; 2008 Feb; 61(2):243-50. PubMed ID: 17393164
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
17. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
19. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
[TBL] [Abstract][Full Text] [Related]
20. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
